Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases

Drugs of Today

Volumn 35, Issue 7, 1999, Pages 519-535

  Crocker, I Caroline ^a   Townley, Robert G ^a,b  

^a CREIGHTON UNIVERSITY   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; 8 METHOXYQUINOLINE 5 [N 2,5 DICHLOROPYRIDIN 3 YL]CARBOXAMIDE; ATIZORAM; AWD 12281; CILOMILAST; D 22888; D 4418; LOTEPREDNOL ETABONATE; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; ROLIPRAM; UNCLASSIFIED DRUG;

ALLERGY; ANTIINFLAMMATORY ACTIVITY; ATOPY; BINDING SITE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG BINDING; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW;

EID: 0032854108     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.7.548265     Document Type: Review

References (137)

1. Barnes, P.J. Cyclic nucleotides and phosphodiesterases and airway function. Eur Respir J 1995, 8:457-62.
2. Foreman, J.C. Cyclic nucleotides as signal transducers. In: Textbook of Receptor Pharmacology. J.C. Foreman, T. Johansen (Eds.). CRC Press: Boca Raton 1996, 239-53.
3. Torphy, T.J. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998, 157: 351-70.
4. Beavo, J.A. Multiple isozymes of cyclic nucleotide phosphodiesterase. Adv Second Messenger Phosphoprotein Res 1988, 22: 1-38.
5. + gene. Proc Natl Acad Sci USA 1989, 86: 3604-8.
6. Colicelli, J., Birchmeier, C., Michaeli, T., O'Neill, K., Riggs, M., Wigler, M. Isolation and characterization of a mammalian gene encoding a high-affinity cAMP phosphodiesterase. Proc Natl Acad Sci USA 1989, 86: 3599-603.
7. Gantner, F., Tenor, H., Gekeler, V., Schudt, C., Wendel, A., Hatzelmann, A. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: A comparative study. J Allergy Clin Immunol 1997, 100: 527-35.
8. Engels, P., Fichtel, K., Lubbert, H. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett 1994, 350: 291-5.
9. Wang, P., Myers, J.G., Wu, P., Cheewatrakoolpong, B., Egan, R.W., Billah, M.M. Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D. Biochem Biophys Res Commun 1997, 234: 320-4.
10. Alvarez, R., Sette, C., Yang, D. et al. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol Pharmacol 1995, 48: 616-22.
11. Torphy, T.J., Zhou, H.L., Cieslinski, L.B. Stimulation of β-adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. J Pharmacol Exp Ther 1992, 263: 1195-205.
12. Manning, C.D., McLaughlin, M.M., Livi, G.P., Cieslinski, L.B., Torphy, T.J., Barnette, M.S. Prolonged β-adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B. J Pharmacol Exp Ther 1996, 276: 810-8.
13. DeBruyne, L.A., Ensley, R.D., Olsen, S.L. et al. Increased frequency of alloantigen-reactive helper T lymphocytes is associated with human cardiac allograft rejection. Transplantation 1993, 56: 722-7.
14. Tenor, H., Schudt, C. Analysis of PDE isoenzyme profiles in cells and tissues. Pharmacological methods. In: Phospho-diesterase Inhibitors. C. Schudt, G. Dent, G.F. Rabe (Eds.). Academic Press: London 1996.
15. Schudt, C., Tenor, H., Hatzelmann, A. PDE isoenzymes as targets for anti-asthma drugs. Eur Respir J 1995, 8: 1179-83.
16. Truong, V.H., Muller, T. Isolation, biochemical characterization and N-terminal sequence of rolipram-sensitive cAMP phosphodiesterase from human mononuclear leukocytes. FEBS Lett 1994, 353: 113-8.
17. Marcoz, P., Nemoz, G., Prigent, A.F., Lagarde, M. Phosphatidic acid stimulates the rolipram-sensitive cyclic nucleotide phosphodiesterase from rat thymocytes. Biochim Biophys Acta 1993, 1176: 129-36.
18. Nemoz, G., Sette, C., Conti, M. Selective activation of rolipram-sensitive, cAMP-specific phosphodiesterase isoforms by phosphatidic acid. Mol Pharmacol 1997, 51: 242-9.
19. Schneider, H.H., Schmiechen, R., Brezinski, M., Seidler, J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 1986, 127: 105-15.
20. Torphy, T.J., Stadel, J.M., Burman, M. et al. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J Biol Chem 1992, 267: 1798-804.
21. McLaughlin, M.M., Cieslinski, L.B., Burman, M., Torphy, T.J., Livi, G.P. A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA. J Biol Chem 1993, 268: 6470-6.
22. Jacobitz, S., McLaughlin, M.M., Livi, G.P., Burman, M., Torphy, T.J. Mapping the functional domains of human recombinant phosphodiesterase 4A: Structural requirements for catalytic activity and rolipram binding. Mol Pharmacol 1996, 50: 891-9.
23. 3H]R-(-)-rolipram binding by selective inhibitors. Biochem J 1996, 318: 425-36.
24. Souness, J.E., Rao, S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 1997, 9: 227-36.
25. Barnette, M.S., Christensen, S.B., Essayan, D.M. et al. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions. J Pharmacol Exp Ther 1998, 284: 420-6.
26. + T cells by IL-16 and IL-2. J Immunol 1998, 160: 2115-20.
27. Kaliner, M., Shelhamer, J.H., Davis, P.B., Smith, L.J., Venter, J.C. Autonomic nervous system abnormalities and allergy [clinical conference]. Ann Intern Med 1982, 96: 349-57.
28. Meurs, H., Kauffman, H.F., Koeter, G.H., Timmermans, A., De Vries, K. Regulation of the β-receptor-adenylate cyclase system in lymphocytes of allergic patients with asthma: Possible role for protein kinase C in allergen-induced nonspecific refractoriness of adenylate cyclase. J Allergy Clin Immunol 1987, 80:326-39.
29. White, M.V. Nasal cholinergic hyperresponsiveness in atopic subjects studied out of season. J Allergy Clin Immunol 1993, 92: 278-87.
30. Safko, M.J., Chan, S.C., Cooper, K.D., Hanifin, J.M. Heterologous desensitization of leukocytes: A possible mechanism of β-adrenergic blockade in atopic dermatitis. J Allergy Clin Immunol 1981, 68: 218-25.
31. Chan, S.C., Hanifin, J.M., Holden, C.A., Thompson, W.J., Hirshman, C.A. Elevated leukocyte phosphodiesterase as a basis for depressed cyclic adenosine monophosphate responses in the Basenji greyhound dog model of asthma. J Allergy Clin Immunol 1985, 76: 148-58.
32. Butler, J.M., Chan, S.C., Stevens, S., Hanifin, J.M. Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. J Allergy Clin Immunol 1983, 71: 490-7.
33. Cooper, K.D., Kang, K., Chan, S.C., Hanifin, J.M. Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro. J Invest Dermatol 1985, 84: 477-82.
34. Cracker, I.C., Gupta, K., Townley, R.G., Khan, M.M. The profile of the cytokines secreted during the generation of T-helper cell lines from atopic asthmatic subjects. J Asthma 1998, 35: 187-201.
35. Chan, S.C., Li, S.H., Hanifin, J.M. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J Invest Dermatol 1993, 100: 681-4.
36. Crocker, I.C., Church, M.K., Ohia, S.E., Townley, R.G. Elevated phosphodiesterase activity may be a consequence, not a cause, of allergy. Ann Allergy Asthma Immunol 1999, submitted.
37. Crocker, I.C., Church, M.K., Ohia, S.E., Townley, R.G. Elevated phosphodiesterase activity in atopy. J Allergy Clin Immunol 1999, 103: Abst S195.
38. Holden, C.A., Chan, S.C., Hanifin, J.M. Monocyte localization of elevated cAMP phosphodiesterase activity in atopic dermatitis. J Invest Dermatol 1986, 87: 372-6.
39. Chan, S.C., Hanifin, J.M. Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes. J Lab Clin Med 1993, 121: 44-51.
40. Grewe, S.R., Chan, S.C., Hanifin, J.M. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: A possible mechanism for cyclic AMP-agonist hyporesponsiveness. J Allergy Clin Immunol 1982, 70: 452-7.
41. Chan, S.C., Grewe, S.R., Stevens, S.R., Hanifin, J.M. Functional desensitization due to stimulation of cyclic AMP-phosphodiesterase in human mononuclear leukocytes. J Cyclic Nucleotide Res 1982, 8: 211-24.
42. Heskel, N.S., Chan, S.C., Thiel, M.L., Stevens, S.R., Casperson, L.S., Hanifin, J.M. Elevated umbilical cord blood leukocyte cyclic adenosine monophosphate-phosphodiesterase activity in children with atopic parents. J Am Acad Dermatol 1984, 11: 422-6.
43. Rousset, F., Robert, J., Andary, M. et al. Shifts in interleukin-4 and interferon-gamma production by T cells of patients with elevated serum IgE levels and the modulatory effects of these lymphokines on spontaneous IgE synthesis. J Allergy Clin Immunol 1991, 87: 58-69.
44. Crocker, I.C., Ohia, S.E., Church, M.K., Townley, R.G. Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors. J Allergy Clin Immunol 1998, 102: 797-804.
45. Banner, K.H., Roberts, N.M., Page, C.P. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis. Br J Pharmacol 1995, 116: 3169-74.
46. Piccinni, M.P., Mecacci, F., Sampognaro, S. et al. Aeroallergen sensitization can occur during fetal life. Int Arch Allergy Immunol 1993, 102:301-3.
47. Holden, C.A., Yuen, C.T. Response of mononuclear leukocyte cyclic adenosine monophosphate-phosphodiesterase activity to treatment with topical fluorinated steroid ointment in atopic dermatitis. J Am Acad Dermatol 1989, 21:69-74.
48. + T cells, Int Arch Allergy Immunol 1999, submitted.
49. + T-cells and-T-helper type 2 cells (TH2), but not in A549 cells. Am J Respir Crit Care Med 1997, 155: Abst A542.
50. + T cells from atopic and nonatopic donors. Am Rev Respir Crit Care Med 1999, 159: Abst A662.
51. Persson, C.G. Overview of effects of theophylline. J Allergy Clin Immunol 1986, 78: 780-7.
52. Barnes, P.J., Pauwels, R.A. Theophylline in the management of asthma: Time for reappraisal? Eur Respir J 1994, 7: 579-91.
53. Scordamaglia, A., Ciprandi, G., Ruffoni, S. et al. Theophylline and the immune response: In vitro and in vivo effects. Clin Immunol Immunopathol 1988, 48: 238-46.
54. Mary, D., Aussel, C., Ferrua, B., Fehlmann, M. Regulation of interleukin 2 synthesis by cAMP in human T cells. J Immunol 1987, 139: 1179-84.
55. Kidney, J., Dominguez, M., Taylor, P.M., Rose, M., Chung, K.F., Barnes, P.J. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995, 151: 1907-14.
56. Crescioli, S., Spinazzi, A., Plebani, M. et al. Theophylline inhibits early and late asthmatic reactions induced by allergens in asthmatic subjects. Ann Allergy 1991, 66: 245-51.
57. Nicholson, C.D., Challiss, R.A., Shahid, M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 1991, 12: 19-27.
58. Torphy, T.J., Livi, G.P., Balcarek, J.M., White, J.R., Chilton, F.H., Undem, B.J. Therapeutic potential of isozyme-selective phosphodiesterase inhibitors in the treatment of asthma. Adv Second Messenger Phosphoprotein Res 1992, 25:289-305.
59. Turner, C.R., Andresen, C.J., Smith, W.B., Watson, J.W. Effects of rolipram on responses to acute and chronic antigen exposure in monkeys. Am J Respir Crit Care Med 1994, 149: 1153-9.
60. Montana, J.G., Cooper, N., Dyke, H.J. et al. PDE4 inhibitors: New xanthine analogues. Bioorg Med Chem Lett 1998, 8: 2925-30.
61. Bacher, E., Boer, C., Bray French, K. et al. N-Aryl rolipram derivatives as potent and selective PDE4 inhibitors. Bioorg Med Chem Lett 1998, 8: 3229-34.
62. Hulme, C., Moriarty, K., Miller, B. et al. The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I. Bioorg Med Chem Lett 1998, 8: 1867-72.
63. Hulme, C., Poli, G.B., Huang, F.C., Souness, J.E., Djuric, S.W. Quaternary substituted PDE4 inhibitors I: The synthesis and in vitro evaluation of a novel series of oxindoles. Bioorg Med Chem Lett 1998, 8: 175-8.
64. Hulme, C., Moriarty, K., Huang, F.C. et al. Quaternary substituted PDE IV inhibitors II: The synthesis and in vitro evaluation of a novel series of γ-lactams. Bioorg Med Chem Lett 1998, 8:399-404.
65. Crespo, M.I., Pages, L., Vega, A. et al. Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors. J Med Chem 1998, 41: 4021-35.
66. Segarra, V., Crespo, M.I., Pujol, F. et al. Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds. Bioorg Med Chem Lett 1998, 8: 505-10.
67. Montana, J.G., Buckley, G.M., Cooper, N. et al. Aryl sulfonamides as selective PDE4 inhibitors. Bioorg Med Chem Lett 1998, 8: 2635-40.
68. Regan, J., Bruno, J., McGarry, D. et al. 2-Substituted-4-methoxybenzimidazole-base d PDE4 inhibitors. Bioorg Med Chem Lett 1998, 8: 2737-42.
69. Gantner, F., Kupferschmidt, R., Schudt, C., Wendel, A., Hatzelmann, A. In vitro differentiation of human monocytes to macrophages: Change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. Br J Pharmacol 1997, 121: 221-31.
70. Molnar Kimber, K., Yonno, L., Heaslip, R., Weichman, B. Modulation of TNF-α and IL-1β from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions 1993, 39(Spec No): C77-9.
71. Kambayashi, T., Jacob, C.O., Zhou, D., Mazurek, N., Fong, M., Strassmann, G. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-γ and IL-6 release by endotoxin-stimulated macrophages. J Immunol 1995, 155: 4909-16.
72. Dent, G., Giembycz, M.A., Rabe, K.F., Wolf, B., Barnes, P.J., Magnussen, H. Theophylline suppresses human alveolar macrophage respiratory burst through phosphodiesterase inhibition. Am J Respir Cell Mol Biol 1994, 10: 565-72.
73. Germain, N., Bertin, B., Legendre, A. et al. Selective phosphodiesterase inhibitors modulate the activity of alveolar macrophages from sensitized guinea-pigs. Eur Respir J 1998, 12: 1334-9.
74. Kelly, J.J., Barnes, P.J., Giembycz, M.A. Characterization of phosphodiesterase 4 in guinea-pig macrophages: Multiple activities, association states and sensitivity to selective inhibitors. Br J Pharmacol 1998, 124: 129-40.
75. Montana, J., Cooper, N., Dyke, H. et al. Activity of D4418, a novel phosphodiesterase 4 (PDE4) inhibitor: Effects in cellular and animal models of asthma and early clinical studies. Am J Respir Crit Care Med 1999, 159: Abst A624.
76. Teixeira, M.M., Miotla, J.M., Cooper, N., Gristwood, R.W., Hellewell, P.G. A comparison of the inhibitory activity of selective PDE4 inhibitors on eosinophil recruitment in guinea pig skin. Mem Inst Oswaldo Cruz 1997, 92(Suppl. 2): 193-6.
77. Tanimoto, Y., Maruo, H., Bewtra, A.K., Townley, R.G. Effects of phosphodiesterase IV inhibitor (WAY-PDA-641) on human eosinophil and neutrophil migration in vitro. J Allergy Clin Immunol 1994, 93: Abst A570.
78. Dent, G., Poppe, H., Egerland, J. et al. Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. Pulm Pharmacol Ther 1998, 11: 13-21.
79. Hatzelmann, A., Tenor, H., Schudt, C. Differential effects of non-selective and selecfive phosphodiesterase inhibitors on human eosinophil functions. Br J Pharmacol 1995, 114: 821-31.
80. Blease, K., Burke Gaffney, A., Hellewell, P.G. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Br J Pharmacol 1998, 124: 229-37.
81. Crocker, I.C., Townley, R.G., Khan, M.M. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. Immune-pharmacology 1996, 31:223-35.
82. Essayan, D.M., Huang, S.K., Kagey Sobotka, A., Lichtenstein, L.M. Differential efficacy of lymphocyte-and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. J Allergy Clin Immunol 1997, 99: 28-37.
83. Rivkin, I., Neutze, J.A. Influence of cyclic nucleotides and a phosphodiesterase inhibitor on in vitro human blood neutrophil chemotaxis. Arch Int Pharmacodyn Ther 1977, 228: 196-204.
84. Kaminuma, O., Kikkawa, H., Matsubara, S., Ikezawa, K. Effect of T-440, a novel type IV phosphodiesterase inhibitor, on allergen-induced immediate and late asthmatic reaction and leukocyte infiltration into the airways of guinea pigs. Int Arch Allergy Immunol 1997, 112: 406-11.
85. Nielson, C.P., Vestal, R.E., Sturm, R.J., Heaslip, R. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol 1990, 86: 801-8.
86. Au, B.T., Teixeira, M.M., Collins, P.D., Williams, T.J. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: Synergism with prostanoids and salbutamol. Br J Pharmacol 1998, 123: 1260-6.
87. Gibbs, B.F., Haas, H., Falcone, F.H. et al. Purified human peripheral blood basophils release interleukin-13 and preformed inter-leukin-4 following immunological activation. Eur J Inununol 1996, 26: 2493-8.
88. Maruo, H., Tanimoto, Y., Bewtra, A.K., Townley, R.G. Effect of phosphodiesterase IV inhibitor (WAY-PDA-641) on PAF-induced superoxide generation from human basophils. J Allergy Clin Immunol 1994, 93: Abst A569.
89. Peachell, P.T., Undem, B.J., Schleimer, R.P. et al. Preliminary identification and role of phosphodiesterase isozymes in human basophils. J Immunol 1992, 148: 2503-10.
90. Shichijo, M., Shimizu, Y., Hiramatsu, K., Inagaki, N., Tagaki, K., Nagai, H. Cyclic AMP-elevating agents inhibit mite-antigen-induced IL-4 and IL-13 release from basophil-enriched leukocyte preparation. Int Arch Allergy Immunol 1997, 114: 348-53.
91. Wright, L.C., Seybold, J., Robichaud, A., Adcock, I.M., Barnes, P.J. Phosphodiesterase expression in human epithelial cells. Am J Physiol 1998, 275: L694-700.
92. Rassier, M.E., McIntyre, S.J., Yamaki, M., Takeda, S., Lin, J.T., Dousa, T.P. Isozymes of cyclic-3′,5′nucleotide phosphodiesterases in renal epithelial LLC-PK1 cells. Kidney Int 1992, 41: 88-99.
93. Suttorp, N., Weber, U., Welsch, T., Schudt, C. Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J Clin Invest 1993, 91: 1421-8.
94. Giembycz, M.A., Corrigan, C.J., Kay, A.B., Barnes, P.J. Inhibition of CD4 and CD8 T-lymphocyte (T-LC) proliferation and cytokine secretion by isoenzyme selective phosphodiesterase (PDE) inhibitors: Correlation with intracellular cyclic AMP (cAMP) concentrations. J Allergy Clin Immunol 1994, 93: Abst 167.
95. Giembycz, M.A., Kelly, J.J. Current status of cyclic nucleotide phosphodiesterase isoenzymes. In: Methylxanthines and Phosphodiesterase Inhibitors in the Treatment of Airways Disease. J. Costello, P.J. Piper (Eds.). Parthenum Press: Lancaster 1994, 27-80.
96. Lewis, G.M., Caccese, R.G., Heaslip, R.J., Bansbach, C.C. Effects of rolipram and CI-930 on IL-2 mRNA transcription in human Jurkat cells. Agents Actions 1993, 39(Spec No): C89-92.
97. 2+ concentrations in human lymphocytes. Br J Pharmacol 1991, 103: 1288-94.
98. 2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2Rα gene expression at multiple levels. J Immunol 1992, 148: 2845-52.
99. Akagi, K., Kohi, F., Trivedi, R., Townley, R.G. Pharmacologic modulation of spontaneous histamine release. Ann Allergy 1989, 63: 39-46.
100. Verghese, M.W., McConnell, R.T., Lenhard, J.M., Harnacher, L., Jin, S.L. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol Pharmacol 1995, 47: 1164-71.
101. Muñoz, E., Zubiaga, A.M., Merrow, M., Sauter, N.P., Huber, B.T. Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-mediated activation: Role of cAMP in T cell proliferation. J Exp Med 1990, 172: 95-103.
102. Van der Pouw Kraan, T., Van Kooten, C., Rensink, I., Aarden, L. Interleukin (IL)-4 production by human T cells: Differential regulation of IL-4 vs. IL-2 production. Eur J Immunol 1992, 22: 1237-41.
103. Rott, O., Cash, E., Fleischer, B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1-but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 1993, 23: 1745-51.
104. Lappin, D., Riches, D.W., Damerau, B., Whaley, K. Cyclic nucleotides and their relationship to complement-component-C2 synthesis by human monocytes. Biochem J 1984, 222: 477-86.
105. Essayan, D.M., Kagey Sobotka, A., Lichtenstein, L.M., Huang, S.K. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Pharmacol Exp Ther 1997, 282: 505-12.
106. 2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol 1993, 150:5321-9.
107. Van Furth, A.M., Seijmonsbergen, E.M., Langermans, J.A., Van der Meide, P.H., Van Furdi, R. Effect of xanthine derivates and dexamethasone on Streptococcus pneumoniae-stimulated production of tumor necrosis factor-α, interleukin-1β (IL-1β), and IL-10 by human leukocytes. Clin Diagn Lab Immunol 1995, 2: 689-92.
108. Raeburn, D., Underwood, S.L., Lewis, S.A. et al. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol 1994, 113: 1423-31.
109. Sanjar, S., Aoki, S., Boubekeur, K. et al. Eosinophil accumulation in pulmonary airways of guinea-pigs induced by exposure to an aerosol of platelet-activating factor: Effect of anti-asthma drugs. Br J Pharmacol 1990, 99: 267-72.
110. Schudt, C., Winder, S., Eltze, M., Kilian, U., Beume, R. Zardaverine: A cyclic AMP specific PDE III/IV inhibitor. Agents Actions Suppl 1991, 34: 379-402.
111. Underwood, D.C., Osborn, R.R., Novak, L.B. et al. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J Pharmacol Exp Ther 1993, 266: 306-13.
112. Elwood, W., Sun, J., Barnes, P.J., Giembycz, M.A., Chung, K.F. Inhibition of allergen-induced lung eosinophilia by type-III and combined type III-and IV-selective phosphodiesterase inhibitors in Brown-Norway rats. Inflamm Res 1995, 44: 83-6.
113. Griswold, D.E., Webb, E.F., Breton, J., White, J.R., Marshall, P.J., Torphy, T.J. Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response. Inflammation 1993, 17: 333-44.
114. Gozzard, N., El Hashim, A., Herd, C.M. et al. Effect of the glucocorticosteroid budesonide and a novel phosphodiesterase type 4 inhibitor CDP840 on antigen-induced airway responses in neonatally immunised rabbits. Br J Pharmacol 1996, 118: 1201-8.
115. Kawasaki, A., Hoshino, K., Osaki, R., Mizushima, Y., Yano, S. Effect of ibudilast: A novel antiasthmatic agent, on airway hypersensitivity in bronchial asthma. J Asthma 1992, 29: 245-52.
116. Condino Neto, A., Vilela, M.M., Cambiucci, E.C. et al. Theophylline therapy inhibits neutrophil and mononuclear cell chemotaxis from chronic asthmatic children. Br J Clin Pharmacol 1991, 32: 557-61.
117. Sullivan, P., Bekir, S., Jaffar, Z., Page, C., Jeffery, P., Costello, J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994, 343: 1006-8.
118. Stawiski, M.A., Rusin, L.J., Burns, T.L., Weinstein, G.D., Voorhees, J.J. Ro 20-1724: An agent that significantly improves psoriatic lesions in double-blind clinical trials. J Invest Dermatol 1979, 73: 261-3.
119. He, W., Huang, F.C., Hanney, B. et al. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors. J Med Chem 1998, 41: 4216-23.
120. Souness, J.E., Griffin, M., Maslen, C. et al. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF-α generation from human monocytes by interacting with a low-affinity phosphodiesterase 4 conformer. Br J Pharmacol 1996, 118: 649-58.
121. Gantner, F., Gotz, C., Gekeler, V., Schudt, C., Wendel, A., Hatzelmann, A. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br J Pharmacol 1998, 123: 1031-8.
122. Ferlenga, P., Biasni, I., Marchini, F., Semeraro, C., Fehlmann, M. Differential ability of PDE4 inhibitors in preventing antigen-induced bronchospasm in guinea pigs. J Allergy Clin Immunol 1999, 103: Abst S127.
123. Wright, K.F., Turner, C.R., Jayasinghe Beck, R., Cohen, V.L., Cheng, J.B., Watson, J.W. Differential in vivo and in vitro bronchorelaxant activities of CP-80,633, a selective phosphodiesterase 4 inhibitor. Can J Physiol Pharmacol 1997, 75: 1001-8.
124. Perry, M.J., O'Connell, J., Walker, C. et al. CDP-840: A novel inhibitor of PDE-4. Cell Biochem Biophys 1998, 29: 113-32.
125. Jones, T.R., McAuliffe, M., McFarlane, C.S., Piechuta, H., Macdonald, D., Rodger, I.W. Effects of a selective phosphodiesterase IV inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthma. Can J Physiol Pharmacol 1998, 76: 210-7.
126. Griswold, D.E., Webb, E.F., Badger, A.M. et al. SB-207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther 1998, 287: 705-11.
127. 4-induced mobilization of peripheral neutrophils in rabbits. Am J Respir Crit Care Med 1999, 159: Abst A90.
128. Underwood, D.C., Bochnowicz, S., Osborn, R.R. et al. Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB-207499 (Ariflo) in the guinea pig. J Pharmacol Exp Ther 1998, 287: 988-95.
129. Christensen, S.B., Guider, A., Forster, C.J. et al. 1,4-Cyclohexanecarboxylates: Potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. J Med Chem 1998, 41: 821-35.
130. Compton, C., Cedar, E., Nieman, R.B., Amit, O., Langley, S.J., Sapene, M. Ariflo improves pulmonary function in patients with asthma: Results of a study in patients taking inhaled corticosteroids. Am J Respir Crit Care Med 1999, 159: Abst A624.
131. Marx, D., Poppe, H., Szelenyi, I. The in vivo activity of AWD-12-281, a potent PDE inhibitor for the treatment of allergic asthma. J Allergy Clin Immunol 1999, 103: Abst S127.
132. Poppe, H., Kusters, S., Szelenyi, I. Effect of AWD-12-281, a new selective PDE4-inhibitor, loteprednol and beclomethasone in models of allergic rhinitis and airway inflammation in Brown Norway rats. Am J Respir Crit Care Med 1999, 159: Abst A95.
133. Schmidt, D., Szelenyi, I., Poppe, H., Magnussen, H., Rabe, K.F. Effect of a novel PDE4 inhibitor AWD-12-281 on allergen induced contractions in passively sensitized human airways. Am J Respir Crit Care Med 1999, 159: Abst A854.
134. Montana, J. et al. Mediators Inflamm 1999, 8(Suppl. 1): Abst S-04-2.
135. Soderling, S.H., Bayuga, S.J., Beavo, J.A. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci USA 1998, 95: 8991-6.
136. Hayashi, M., Matsushima, K., Ohashi, H. et al. Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3′,5′-cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun 1998, 250: 751-6.
137. Dousa, T.P. Cydic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int 1999, 55: 29-62.